NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

IVD市場更新和COVID-19的影響:2021年

2021 IVD Market Update and COVID-19 Impact

出版商 Kalorama Information 商品編碼 1006560
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
IVD市場更新和COVID-19的影響:2021年 2021 IVD Market Update and COVID-19 Impact
出版日期: 2021年03月12日內容資訊: 英文
簡介

本報告提供IVD產品市場上最新的更新,包含以下類別的相關市場規模,系統性資訊。

  • 臨床化學
  • 免疫測量 - 非同位素
  • 感染疾病
  • 其他免疫
  • 血液銀行篩檢
  • 藥物濫用
  • 糖尿病HbA1c - 實驗室
  • 血液學 - 核心實驗室
  • 微生物學 (ID/AST)
  • 微生物學 (分子)
  • 微生物學 - 質譜分析
  • 無線電免疫測量
  • 凝固 (PT/INR)
  • 凝固,分子
  • 組織學/細胞學
  • HPV,分子
  • 核酸化驗
  • 血型判斷
  • 血液銀行分子
  • NAT血液監測器
  • 循環腫瘤細胞
  • POC,OTC糖尿病
  • POC,OTC及其他
  • POC,專門/醫院
  • COVID-19


目錄

第1章 全球IVD市場 - 2020年的更新

  • COVID-19
  • IVD市場概況和COVID-19的影響

第2章 產品趨勢新的開發

  • 新的核心IVD產品的銷售與開發
    • 臨床化學
    • 血液學
    • 腫瘤學
    • 凝固
    • 免疫測量
    • 微生物學
    • 組織學
    • 分子專門
    • POC
    • 質譜分析
  • COVID-19開發
    • 抗原
    • 血清
    • 分子

第3章 主要IVD市場企業的發展

  • 主要的競爭領導者
    • ABBOTT
    • AIDIAN OY
    • BECTON DICKINSON AND CO
    • BIOMERIEUX SA
    • DANAHER
    • HOLOGIC, INC.
    • ILLUMINA
    • ORTHO CLINICAL DIAGNOSTICS
    • PERKIN ELMER
    • QUIDEL CORPORATION
    • ROCHE DIAGNOSTIC
    • THERMO FISHER SCIENTIFIC

第4章 新的機會

  • 遠程醫療、遠端患者監護
  • 償付的選項的擴大
  • POC
目錄
Product Code: 21-016
  • What is the Size of the IVD Market in 2021?
  • What Impact has COVID-19 Had on IVD Markets?
  • What Major Trends are Affecting the Market in 2021?

Diagnostic test products have never been more important. This report, “ 2021 IVD Market Update and COVID-19 Impact”, is an update of the market for in vitro diagnostics products from Kalorama's analysts to reflect the latest information. As part of its coverage, this report contains market sizing for the following categories of IVD:

  • Clinical Chemistry
  • Immunoassays- non isotopic
  • Infectious disease
  • Other immunos
  • Blood bank screening
  • Drugs of Abuse
  • Diabetes HbA1c - lab
  • Hematology - Core Lab
  • Microbiology (ID/AST)
  • Microbiology (molecular)
  • Microbiology - Mass Spectrometry
  • Radioimmunoassays
  • Coagulation (PT/INR)
  • Coagulation, molecular
  • Histology/cytology
  • HPV, molecular
  • Nucleic acid assays
  • Blood grouping/typing
  • Blood bank molecular
  • NAT Blood Screens
  • Circulating tumor cells
  • POC, OTC diabetes
  • POC, OTC other
  • POC, professional/hospital;
  • COVID 19


Complete market figures and forecasts will be part of Kalorama's Worldwide report in August.

How is COVID-19 Impacting the Market in 2021

This report does detail the effects of COVID-19 including the following:

  • Effect of COVID-19 on Market Segments
  • Table 1-3: IVD Market excluding and with COVID-19, 2020
  • Figure 1-1: IVD Market Distribution by Segment
  • Table 1-4: Global In Vitro Diagnostic Market - YoY Growth 2019-2020
  • Figure 1-2: Global In Vitro Diagnostic Market - YoY Growth 2019-2020
  • Figure 1-3: IVD Segment Performance, Q1 2020 - Q4 2020
  • Figure 1-4: IVD Segment Performance, Total Market Value, 2020

Also included in this report:

  • Product Trends and Developments
  • COVID-19 Developments Sept. 2020 to Feb 2021
  • Select IVD Market Participant Developments
  • Competitive Leader Updates

Companies covered in this report include:

  • Abbott
  • Aidian Oy
  • Becton Dickinson and Co
  • Biomérieux SA
  • Danaher
  • Hologic, Inc.
  • Illumina
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Quidel Corporation
  • Roche Diagnostic
  • Thermo Fisher Scientific

TABLE OF CONTENTS

ONE: WORLDWIDE IVD MARKET - 2020 UPDATE

  • Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2020 ($ million) (Clinical Chemistry; Immunoassays- non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Radioimmunoassays; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry)
  • COVID 19
  • Table 1-2: COVID-19 Product Sales - Immunoassay (Antigen, Serology), Molecular, POC), 2020 ($ millions)
  • IVD MARKET HIGHLIGHTS AND EFFECTS OF COVID-19
    • Effect of COVID-19 on Market Segments
      • Table 1-3: IVD Market excluding and with COVID-19, 2020
      • Figure 1-1: IVD Market Distribution by Segment
      • Table 1-4: Global In Vitro Diagnostic Market - YoY Growth 2019-2020
      • Figure 1-2: Global In Vitro Diagnostic Market - YoY Growth 2019-2020
      • Figure 1-3: IVD Segment Performance, Q1 2020 - Q4 2020
      • Figure 1-4: IVD Segment Performance, Total Market Value, 2020

TWO: PRODUCT TRENDS AND NEW DEVELOPMENTS

  • NEW CORE IVD PRODUCT LAUNCHES AND DEVELOPMENTS
    • Clinical Chemistry
    • Hematology
    • Oncology
    • Coagulation
    • Immunoassay
    • Microbiology
    • Histology
    • Molecular Specialties
    • POC
    • Mass Spectrometry
  • COVID-19 DEVELOPMENTS - SEPTEMBER 2020 - FEBRUARY 2021
    • Figure 2-1: COVID-19 Test Market by Type, Q1-Q4 2020 - Increasing Performance in Antigen and Rapid testing; Molecular Maintains Growth; Serology Runs Steady
    • Antigen
    • Serology
    • Molecular

THREE: SELECTED IVD MARKET PARTICIPANT DEVELOPMENTS

  • SELECTED COMPETITIVE LEADER UPDATES
    • Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2019-2020
    • Figure 3-2: Changes in Market Distribution for IVD Sales, 2019-2020 - Roche Maintains Lead, Abbott Closing Gap
    • ABBOTT
      • Table 3-1: Abbott Corporate Summary
    • AIDIAN OY
      • Table 3-2: Aidian Oy Summary
    • BECTON DICKINSON AND CO
      • Table 3-3: BD Corporate Summary
    • BIOMÉRIEUX SA
      • Table 3-4: bioMerieux Corporate Summary
    • DANAHER
      • Table 3-5: Danaher Corporation Summary
    • HOLOGIC, INC.
      • Table 3-6: Hologic Corporate Summary
    • ILLUMINA
    • Table 3-7: Illumina Corporate Summary
    • ORTHO CLINICAL DIAGNOSTICS
      • Table 3-8: Ortho Clinical Corporate Summary
    • PERKIN ELMER
      • Table 3-9: Perkin Elmer Corporate Summary
    • QUIDEL CORPORATION
      • Table 3-10 : Quidel Corporate Summary
    • ROCHE DIAGNOSTIC
      • Table 3-11: Roche Diagnostic Corporate Summary
    • THERMO FISHER SCIENTIFIC
      • Table 3-12: Thermo Fisher Scientific Corporate Summary

FOUR: NEW OPPORTUNITIES

  • TELEHEALTH AND REMOTE PATIENT MONITORING
  • EXPANDING OPTIONS IN REIMBURSEMENT
  • POC